ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 833,91
-0,09%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) Actualités

IFRX InflaRx NV

1,35
-0,03 (-2,17%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
InflaRx NV IFRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,03 -2,17% 1,35 00:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,40 1,28 1,4492 1,36 1,38
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202413:30GLOBEInflaRx to Host Virtual R&D Event on June 5, 2024 and..
24/4/202413:30GLOBEInflaRx to Participate in Capital One Securities 1st Annual..
21/3/202412:00GLOBEInflaRx Reports Full Year 2023 Results and Announces INF904..
19/3/202412:30GLOBEInflaRx to Announce Development Plans for INF904 and 2023..
22/2/202413:30GLOBEInflaRx Appoints Jan Medina as Head of Investor Relations
25/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202413:30GLOBEInflaRx Announces Initiation of its Commitment Program for..
04/1/202422:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/1/202413:00GLOBEInflaRx Announces Positive Topline Results from the Multiple..
06/11/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202313:30GLOBEInflaRx Announces First Patient Dosed in Phase III Trial..
01/11/202313:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:30GLOBEInflaRx Reports Third Quarter 2023 Financial Results and..
11/9/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202313:00GLOBEInflaRx Announces Positive Topline Results from the Single..
30/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202313:30GLOBEInflaRx’s Marketing Authorization Application (MAA) for..
10/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202313:30GLOBEInflaRx Reports Second Quarter 2023 Financial Results &..
12/7/202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/7/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30/6/202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
28/6/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/6/202313:30GLOBEInflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
21/6/202313:00GLOBEInflaRx Announces Commercial Launch of Gohibic (vilobelimab)..
11/5/202313:30GLOBEInflaRx Reports First Quarter 2023 Financial and Operating..

Dernières Valeurs Consultées

NASDAQ
IFRX
InflaRx NV
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés